June 3, 2021

Afimmune Announces Positive Data with Epeleuton from Preclinical Atherosclerosis Studies

Data show large decreases in atherosclerotic plaque following treatment with epeleuton Dublin, Ireland, 3rd June 2021 – Afimmune, a clinical stage drug discovery company focused on […]
December 18, 2018

Afimmune receives method of use patent allowance for Oral AF102 in the US

Dublin, Ireland, 18th December 2018 – Afimmune, a privately held clinical stage drug discovery and development company, today announced receipt of allowance for a patent application in […]